Literature DB >> 23959274

Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain.

A Llerena1, M Alvarez2, P Dorado3, I González2, E Peñas-LLedó3, B Pérez2, J Cobaleda4, L R Calzadilla5.   

Abstract

The aims of this study were to evaluate the diclofenac metabolism in Hispanics from Cuba and Spain and its relation to ethnicity, CYP2C9 genotypes and environmental factors. Diclofenac hydroxylation capacity (concentration ratios of diclofenac/metabolites in 8-h urine) was studied in 160 Cuban (classified as 76 Cuban-Whites-CWs and 84 Cuban-Mestizos-CMs) and 148 Spaniard (SPs) healthy volunteers. Diclofenac and its main metabolites, 4'-hydroxy (OH), 3'-OH and 5-OH diclofenac, and CYP2C9*2 to *6 and *8 alleles were also determined in 132 and 128 CWs and CMs, respectively. Gender, tobacco, caffeine and ethanol consumption were also evaluated. The mean diclofenac/4'-OH diclofenac ratio was higher in CMs (0.72±0.25) than in CWs (0.64±0.20; P<0.05) and SPs (0.57±0.26; P<0.001). The mean diclofenac/4'-OH diclofenac ratio was higher (P<0.05) in subjects with CYP2C9*1/*3 (0.77±0.19; n=22) and CYP2C9*1/*8 (0.93±0.33; n=4) genotypes than with CYP2C9*1/*1 (0.65±0.24; n=90). Environmental factors did not seem to influence the diclofenac metabolism in these populations. The present findings show for the first time interethnic differences between Hispanic groups in urinary diclofenac/4'-OH diclofenac ratios, and the relevance of CYP2C9*3 and CYP2C9*8 alleles.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23959274     DOI: 10.1038/tpj.2013.28

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  6 in total

Review 1.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

Review 2.  Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.

Authors:  Karla Claudio-Campos; Jorge Duconge; Carmen L Cadilla; Gualberto Ruaño
Journal:  Drug Metab Pers Ther       Date:  2015-06

Review 3.  Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review.

Authors:  Farzin Zobdeh; Ivan I Eremenko; Mikail A Akan; Vadim V Tarasov; Vladimir N Chubarev; Helgi B Schiöth; Jessica Mwinyi
Journal:  Pharmaceutics       Date:  2022-06-01       Impact factor: 6.525

4.  Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population.

Authors:  Yipeng Ding; Danlei Yang; Long Zhou; Ping He; Jinjian Yao; Pingdong Xie; Daobo Lin; Dingwei Sun; Pei Sun; Quanni Li; Tingting Geng; Tianbo Jin
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 5.  Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population.

Authors:  Weixuan Zhao; Hongmei Meng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

6.  Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population.

Authors:  Fernando de Andrés; Catalina Altamirano-Tinoco; Ronald Ramírez-Roa; Carlos F Montes-Mondragón; Pedro Dorado; Eva M Peñas-Lledó; Adrián LLerena
Journal:  Pharmacogenomics J       Date:  2020-10-06       Impact factor: 3.550

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.